John O Mascarenhas (J Mascarenhas, John Mascarenhas)

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 64

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Histone Deacetylase

Prognostic Factors

Top Venues

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia 38 (5) (2024)
Shivani Handa, Kyle A Farina, Michelle Becker, Brianna Kelly, Ashley Yu, Jonathan Feld, Douglas Tremblay, Bridget K Marcellino, Christian Salib, John O Mascarenhas, Alan H Shih
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO precision oncology 8 (2024)
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas K Gupta, Jean-Jacques Kiladjian, John O Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38 (8) (2024)
Shivani Handa, Kyle A Farina, Michelle Becker, Brianna Kelly, Ashley Yu, Jonathan Feld, Douglas Tremblay, Bridget K Marcellino, Christian Salib, John O Mascarenhas, Alan H Shih
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO precision oncology 8 (2024)
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia 38 (5) (2024)
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas K Gupta, Jean-Jacques Kiladjian, John O Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia (2024)
Myvizhi Esai Selvan, Daniel I Nathan, Daniela Guisado, Giulia Collatuzzo, Sushruta Iruvanti, Paolo Boffetta, John O Mascarenhas, Ronald Hoffman, Louis J Cohen, Bridget K Marcellino, Zeynep Hülya Gümüş
Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis. medRxiv : the preprint server for health sciences (2024)
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas K Gupta, Jean-Jacques Kiladjian, John O Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38 (8) (2024)
Blake Langlais, Amylou C Dueck, Heidi E Kosiorek, Carolyn Mead-Harvey, Eric Meek, Lauren Rogak, John O Mascarenhas, Ruben Mesa, Krisstina Gowin, Jean Palmer, Robyn Scherber, Bridget Marcellino, Ronald Hoffman, Gina L Mazza
Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms. Leukemia & lymphoma (2024)
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia 38 (5) (2024)
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia 38 (5) (2024)
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Carlos Hernández-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas K Gupta, Claire N Harrison, Elizabeth O Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus M Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O Mascarenhas, Lucia Masarova, Ruben A Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T Oh, Animesh D Pardanani, Anand Ashwin Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M Vannucchi, Tiziano Barbui
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood (2024)
Shivani Handa, Kyle A Farina, Michelle Becker, Brianna Kelly, Ashley Yu, Jonathan Feld, Douglas Tremblay, Bridget K Marcellino, Christian Salib, John O Mascarenhas, Alan H Shih
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO precision oncology 8 (2024)
Myvizhi Esai Selvan, Daniel I Nathan, Daniela Guisado, Giulia Collatuzzo, Sushruta Iruvanti, Paolo Boffetta, John O Mascarenhas, Ronald Hoffman, Louis J Cohen, Bridget K Marcellino, Zeynep Hülya Gümüş
Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis. medRxiv : the preprint server for health sciences (2024)
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas K Gupta, Jean-Jacques Kiladjian, John O Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38 (8) (2024)
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas K Gupta, Jean-Jacques Kiladjian, John O Mascarenhas, Vikram Mathews, Francesco Passamonti, Claire Harrison
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38 (8) (2024)
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia (2024)
Douglas Tremblay, John O Mascarenhas
Pharmacotherapeutic advances for splenomegaly in myelofibrosis. Expert opinion on pharmacotherapy (2023)
Douglas Tremblay, John O Mascarenhas
Pharmacotherapeutic advances for splenomegaly in myelofibrosis. Expert opinion on pharmacotherapy (2023)
John O Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K Rampal, Adam J Mead, Gabriella Hobbs, Joseph M Scandura, Moshe Talpaz, Nikki Granacher, Tim C P Somervaille, Ronald Hoffman, Marielle J Wondergem, Mohamed E Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro Maria Maria Vannucchi, Srdan Verstovsek, Natalia Curto-García, Claire N Harrison, Vikas K Gupta
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
John O Mascarenhas, Anna Rita Migliaccio, Heidi E Kosiorek, Rupali Bhave, Jeanne M Palmer, Andrew T Kuykendall, Ruben A Mesa, Raajit K Rampal, Aaron T Gerds, Abdulraheem Yacoub, Kristen Pettit, Moshe Talpaz, Rami S Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Kathryn Johnson, Mikaela Dougherty, Erin M McGovern, Juan Esteban Arango Ossa, Dylan Domenico, Noushin Farnoud, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Alessandro Maria Maria Vannucchi, Francesca Arciprete, Maria Zingariello, Mario Falchi, Mohamed E Salama, Carolyn Mead-Harvey, Amylou C Dueck, Lilian Varricchio, Ronald Hoffman
A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Benjamin O Adegbite, Matthew H Abramson, Victoria Gutgarts, Florin M Musteata, Kinsuk Chauhan, Alecia N Muwonge, Kristin A Meliambro, Steven P Salvatore, Sebastian El Ghaity-Beckley, Marina Kremyanskaya, Bridget Marcellino, John O Mascarenhas, Kirk N Campbell, Lili Chan, Steven G Coca, Ellin M Berman, Edgar A Jaimes, Evren U Azeloglu
Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity. Clinical journal of the American Society of Nephrology : CJASN (2023)
Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John O Mascarenhas, Raajit K Rampal
Moving towards disease modification in polycythemia vera. Blood (2023)
Prithviraj Bose, Andrew T Kuykendall, Carole Miller, Sandra Kurtin, Kyle A Farina, Donald M Harting, John O Mascarenhas, Ruben A Mesa
Moving Beyond Ruxolitinib Failure in Myelofibrosis: Evolving Strategies for Second Line Therapy. Expert opinion on pharmacotherapy (2023)
Douglas Tremblay, Dahiel Sastow, John O Mascarenhas
CNL and aCML are prognostically distinct: a large national cancer database analysis. Blood advances (2023)
John O Mascarenhas, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry, Ali McBride
Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study. Future oncology (London, England) (2023)
Dahniel Sastow, Joshua Tatarian, Yosef J R A Riazat-Kesh, Kyle Farina, Michelle Becker, Jonathan Feld, Marina Kremyanskaya, John O Mascarenhas, Kenneth Byrd, Heather J Male, Tara L Lin, Douglas Tremblay
Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement. Leukemia & lymphoma (2023)
Benjamin O Adegbite, Matthew H Abramson, Victoria Gutgarts, Florin M Musteata, Kinsuk Chauhan, Alecia N Muwonge, Kristin A Meliambro, Steven P Salvatore, Sebastian El Ghaity-Beckley, Marina Kremyanskaya, Bridget Marcellino, John O Mascarenhas, Kirk N Campbell, Lili Chan, Steven G Coca, Ellin M Berman, Edgar A Jaimes, Evren U Azeloglu
Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity. Clinical journal of the American Society of Nephrology : CJASN (2023)
Stephen T Oh, Ruben A Mesa, Claire N Harrison, Prithviraj Bose, Aaron T Gerds, Vikas K Gupta, Bart L Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah A Buckley, Shanthakumar Tyavanagimatt, Bryan G Harder, Karisse Roman-Torres, Jennifer Smith, Adam R Craig, John O Mascarenhas, Srdan Verstovsek
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood advances (2023)
Hassan Awada, Manasa Bhatta, Han Yu, Wenyan Ji, Surui Hou, Tara Cronin, Sheeba Ba Aqeel, Arya Mariam Roy, Muhammad Salman Faisal, Peter Kouides, John O Mascarenhas, Elizabeth A Griffiths, Amro Elshoury
ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms. Leukemia (2023)
Julian A Waksal, Claudia Bruedigam, Rami S Komrokji, Catriona H M Jamieson, John O Mascarenhas
Telomerase-Targeted Therapies in Myeloid Malignancies. Blood advances (2023)
Serena Tharakan, John O Mascarenhas, Douglas Tremblay
Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management. Leukemia & lymphoma (2023)
Vikas K Gupta, John O Mascarenhas, Marina Kremyanskaya, Raajit K Rampal, Moshe Talpaz, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Srdan Verstovsek, Gozde Colak, Debarshi Dey, Claire N Harrison
Matching-adjusted indirect comparison of pelabresib/ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood advances (2023)
Nabih Maslah, Emmanuelle Verger, Stéphane Giraudier, Mathias Chea, Ronald Hoffman, John O Mascarenhas, Bruno Cassinat, Jean-Jacques Kiladjian
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood advances 6 (9) (2022)
Sangeetha Venugopal, John O Mascarenhas
The odyssey of pacritinib in myelofibrosis. Blood advances 6 (16) (2022)
Gabriela S Hobbs, Cansu Cimen Bozkus, Erin Laverne Moshier, Mikaela Dougherty, Michal Bar-Natan, Lonette Sandy, Kathryn Johnson, Julia Elise Foster, Tina Som, Molly Macrae, Hetal D Marble, Mohamed Salama, Siraj M El Jamal, Nicole Zubizarreta, Martha Wadleigh, Richard Stone, Nina Bhardwaj, Camelia Iancu-Rubin, John O Mascarenhas
PD-1 inhibition in advanced myeloproliferative neoplasms. Blood advances 5 (23) (2022)
John O Mascarenhas
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert review of hematology 15 (8) (2022)
John O Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N Harrison, Mary Frances Frances McMullin, Alessandro Maria Maria Vannucchi, Joanne Ewing, Casey L O'Connell, Jean-Jacques Kiladjian, Adam J Mead, Elliott F Winton, David S Leibowitz, Valerio De Stefano, Murat O Arcasoy, Craig M Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max Fine Levine, Juan Esteban Arango Ossa, Erin M McGovern, Lonette Sandy, Mohamad E Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V Penson, Rona Singer Weinberg, Leah Price, Judith D Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K Rampal, Ruben A Mesa, Amylou C Dueck, Ronald Hoffman
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139 (19) (2022)
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit K Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben A Mesa, Andrew T Kuykendall, Alessandro Maria Maria Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Álvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John O Mascarenhas
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future oncology (London, England) 18 (27) (2022)
John O Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron T Gerds, Vikas K Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben A Mesa, Jeanne Palmer, Marta Bellini, David Morrall Ross, Alessandro Maria Maria Vannucchi, Abdulraheem Yacoub
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood advances 6 (4) (2022)
John O Mascarenhas, Srdan Verstovsek
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128 (14) (2022)
Srdan Verstovsek, Haifa Kathrin Al-Ali, John O Mascarenhas, Andrew Charles Perkins, Alessandro Maria Maria Vannucchi, Sanjay R Mohan, Bart L Scott, Dariusz Woszczyk, Steffen Koschmieder, Regina García-Delgado, Rejtő László, Jesse S McGreivy, Wayne P Rothbaum, Jean-Jacques Kiladjian
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future oncology (London, England) (2022)
John O Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder, Alessandro M Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye M Feller, Aleksandra Rizo, Srdan Verstovsek
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future oncology (London, England) 18 (22) (2022)
John O Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, Claire N Harrison, Srdan Verstovsek, Alessandro Maria Vannucchi, Raajit K Rampal, Jean-Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K Schneider, Alan F List
Biological drivers of clinical phenotype in myelofibrosis. Leukemia (2022)
Tiziano Barbui, Valerio De Stefano, Alessandra Carobbio, Alessandra Iurlo, Alberto Alvarez-Larran, Beatriz Cuevas, Francisca Ferrer-Marín, Alessandro Maria Maria Vannucchi, Francesca Palandri, Claire Harrison, Hassan Sibai, Martin Griesshammer, Massimiliano Bonifacio, Elena M Elli, Chiara Trotti, Steffen Koschmieder, Giuseppe Carli, Giulia Benevolo, Jean-Christophe Ianotto, Swati Goel, Anna Falanga, Silvia Betti, Daniele Cattaneo, Eduardo Arellano-Rodrigo, Lara Mannelli, Nicola Vianelli, Andrew J Doyle, Vikas Gupta, Kai Wille, Douglas Tremblay, John O Mascarenhas
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia 35 (10) (2021)
John O Mascarenhas, Rami S Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L Scott, Maria R Baer, Ronald Hoffman, Olatoyosi Odenike, Alessandro M Vannucchi, Jacqueline Bussolari, Eugene Zhu, Esther Rose, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye M Feller, Aleksandra Rizo, Jean-Jacques Kiladjian
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (26) (2021)
John O Mascarenhas
Mutations in MPNs to "interfere-on". Blood 138 (22) (2021)
John O Mascarenhas, Aaron T Gerds, Srdan Verstovsek
Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia 35 (12) (2021)
Pedro Henrique Alves da Silva, Samantha Xing, Andriana G Kotini, Eirini P Papapetrou, Xiaoyu Song, Kai W Wucherpfennig, John O Mascarenhas, Lucas Ferrari de Andrade
MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood (2021)
John Yohan Rhee, Douglas Tremblay, Amy M Chan, Martin S Tallman, John O Mascarenhas
Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review. Blood advances 3 (12) (2020)
Douglas Tremblay, Myron Schwartz, Richard Bakst, Rahul Patel, Thomas Schiano, Marina Kremyanskaya, Ronald Hoffman, John O Mascarenhas
Modern management of splenomegaly in patients with myelofibrosis. Annals of hematology 99 (7) (2020)
Leonard Naymagon, Douglas Tremblay, John O Mascarenhas
Reevaluating the role of ferritin in the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. European journal of haematology 104 (4) (2020)
Sangeetha Venugopal, John O Mascarenhas
Refractory gout in primary myelofibrosis. Blood 133 (23) (2020)
Sangeetha Venugopal, John O Mascarenhas
Novel therapeutics in myeloproliferative neoplasms. Journal of hematology & oncology 13 (1) (2020)
Bridget K Marcellino, John O Mascarenhas
SLAM dunk for myelofibrosis? Blood 134 (10) (2020)
Marina Y Konopleva, Giovanni Martinelli, Naval Daver, Cristina Papayannidis, Andrew H Wei, Brian Higgins, Marion Ott, John O Mascarenhas, Michael Andreeff
MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34 (11) (2020)
Douglas Tremblay, Juan Putra, Alexander Vogel, Adam Winters, Ronald Hoffman, Thomas D Schiano, Maria Isabel Fiel, John O Mascarenhas
The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case reports in hematology 2019 (2019)
John O Mascarenhas, Min Lu, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit Rampal, Amylou C Dueck, Ronald Hoffman
Oral idasanutlin in patients with polycythemia vera. Blood 134 (6) (2019)
John O Mascarenhas, H Kosiorek, J Prchal, A Yacoub, D Berenzon, M R Baer, E Ritchie, R T Silver, C Kessler, E Winton, M C Finazzi, A Rambaldi, A M Vannucchi, D Leibowitz, D Rondelli, M O Arcasoy, R Catchatourian, J Vadakara, V Rosti, E Hexner, M Kremyanskaya, L Sandy, J Tripodi, V Najfeld, N Farnoud, M E Salama, R S Weinberg, R Rampal, J D Goldberg, R Mesa, A C Dueck, R Hoffman
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia 33 (12) (2019)
John O Mascarenhas, Maria R Baer, Craig Kessler, Elizabeth Hexner, Douglas Tremblay, Leah Price, Lonette Sandy, Rona Weinberg, Heike Pahl, Lewis R Silverman, Judith D Goldberg, Heidi Kosiorek, Amylou C Dueck, Ronald Hoffman
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia & lymphoma 60 (5) (2019)
Bridget K Marcellino, Ronald Hoffman, Joseph Tripodi, Min Lu, Heidi Kosiorek, John O Mascarenhas, Raajit K Rampal, Amylou Dueck, Vesna Najfeld
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood advances 2 (24) (2019)
John O Mascarenhas, E Virtgaym, M Stal, H Blacklock, A T Gerds, R Mesa, P Ganly, D Snyder, I Tabbara, D Tremblay, E Moshier
Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Annals of hematology 97 (8) (2018)
A Coltoff, J Houldsworth, A Keyzner, A S Renteria, John O Mascarenhas
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. Annals of hematology 97 (7) (2018)
D C Choi, D Tremblay, C Iancu-Rubin, John O Mascarenhas
Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Annals of hematology 96 (6) (2017)
Damiano Rondelli, Judith D Goldberg, Luis Isola, Leah S Price, Tsiporah B Shore, Michael J Boyer, Andrea Bacigalupo, Alessandro Rambaldi, Marco Scarano, Rebecca B Klisovic, Vikas Gupta, Bjorn Andreasson, John O Mascarenhas, Meir Wetzler, Alessandro M Vannucchi, Josef T Prchal, Vesna Najfeld, Attilio Orazi, Rona S Weinberg, Crystal Miller, Giovanni Barosi, Lewis R Silverman, Giuseppe Prosperini, Roberto Marchioli, Ronald Hoffman
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124 (7) (2014)